Morgan Stanley’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-88,142
| Closed | -$1.68M | – | 6957 |
|
|
2019
Q1 | $1.68M | Buy |
88,142
+87,517
| +14,003% | +$1.42M | ﹤0.01% | 3733 |
|
|
2018
Q4 | $8K | Buy |
625
+375
| +150% | +$4.19K | ﹤0.01% | 6231 |
|
|
2018
Q3 | $3K | Buy |
+250
| New | +$2.5K | ﹤0.01% | 6545 |
|
|
2017
Q1 | – | Sell |
-151,345
| Closed | -$743K | – | 6765 |
|
|
2016
Q4 | $743K | Buy |
151,345
+142,306
| +1,574% | +$729K | ﹤0.01% | 4675 |
|
|
2016
Q3 | $45K | Buy |
9,039
+1,025
| +13% | +$5.25K | ﹤0.01% | 5635 |
|
|
2016
Q2 | $41K | Sell |
8,014
-59,640
| -88% | -$321K | ﹤0.01% | 5593 |
|
|
2016
Q1 | $386K | Buy |
67,654
+25,590
| +61% | +$179K | ﹤0.01% | 4594 |
|
|
2015
Q4 | $437K | Buy |
42,064
+32,744
| +351% | +$444K | ﹤0.01% | 4635 |
|
|
2015
Q3 | $173K | Sell |
9,320
-68,897
| -88% | -$1.33M | ﹤0.01% | 5155 |
|
|
2015
Q2 | $1.52M | Sell |
78,217
-14,524
| -16% | -$257K | ﹤0.01% | 3868 |
|
|
2015
Q1 | $1.63M | Buy |
92,741
+61,561
| +197% | +$1.03M | ﹤0.01% | 3766 |
|
|
2014
Q4 | $499K | Buy |
31,180
+160
| +0.5% | +$2.14K | ﹤0.01% | 4664 |
|
|
2014
Q3 | $391K | Sell |
31,020
-877
| -3% | -$12.5K | ﹤0.01% | 4736 |
|
|
2014
Q2 | $498K | Buy |
31,897
+12,857
| +68% | +$189K | ﹤0.01% | 4575 |
|
|
2014
Q1 | $249K | Buy |
19,040
+13,005
| +215% | +$203K | ﹤0.01% | 5006 |
|
|
2013
Q4 | $97K | Sell |
6,035
-77,813
| -93% | -$1.24M | ﹤0.01% | 5360 |
|
|
2013
Q3 | $1.4M | Buy |
83,848
+73,623
| +720% | +$1.09M | ﹤0.01% | 3513 |
|
|
2013
Q2 | $103K | Buy |
+10,225
| New | +$107K | ﹤0.01% | 5066 |
|
Other funds holding OSIR
Morgan Stanley's OSIR Position: Q2 2019 in Review
Morgan Stanley sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 88,142 shares — an estimated $1.68M sold.
Morgan Stanley first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $1.68M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Morgan Stanley reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Morgan Stanley sold 88,142 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.68M.
- Morgan Stanley first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- Morgan Stanley's Osiris Therapeutics, Inc. Common Stock position peaked at $1.68M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Morgan Stanley's 13F filing for Q2 2019, filed 14 Aug 2019.